ZA985129B - The use of tetrahydrofolates in natural stereoisomeric form for the production of a pharmaceutical preparation suitable for influencing the homocysteine level particularly for asissting the remethylation of homocysteine - Google Patents

The use of tetrahydrofolates in natural stereoisomeric form for the production of a pharmaceutical preparation suitable for influencing the homocysteine level particularly for asissting the remethylation of homocysteine

Info

Publication number
ZA985129B
ZA985129B ZA985129A ZA985129A ZA985129B ZA 985129 B ZA985129 B ZA 985129B ZA 985129 A ZA985129 A ZA 985129A ZA 985129 A ZA985129 A ZA 985129A ZA 985129 B ZA985129 B ZA 985129B
Authority
ZA
South Africa
Prior art keywords
homocysteine
tetrahydrofolates
remethylation
production
pharmaceutical preparation
Prior art date
Application number
ZA985129A
Other languages
English (en)
Inventor
Hans Rudolf Mueller
Martin Ulmann
Rudolf Moser
Original Assignee
Eprova Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=4210897&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA985129(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eprova Ag filed Critical Eprova Ag
Publication of ZA985129B publication Critical patent/ZA985129B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Liquid Crystal Substances (AREA)
ZA985129A 1997-06-13 1998-06-12 The use of tetrahydrofolates in natural stereoisomeric form for the production of a pharmaceutical preparation suitable for influencing the homocysteine level particularly for asissting the remethylation of homocysteine ZA985129B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH01456/97A CH693255A5 (de) 1997-06-13 1997-06-13 Verwendung von Tetrahydrofolaten in der natürlichenstereoisomeren Form zur Herstellung einer pharmazeutischenZubereitung geeignet zur Beeinflussung des Homocystein-Spiegels.

Publications (1)

Publication Number Publication Date
ZA985129B true ZA985129B (en) 1998-12-14

Family

ID=4210897

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA985129A ZA985129B (en) 1997-06-13 1998-06-12 The use of tetrahydrofolates in natural stereoisomeric form for the production of a pharmaceutical preparation suitable for influencing the homocysteine level particularly for asissting the remethylation of homocysteine

Country Status (15)

Country Link
US (1) US6011040A (da)
EP (2) EP0898965B9 (da)
JP (1) JPH11116482A (da)
CN (1) CN102151271A (da)
AT (2) ATE321555T1 (da)
AU (1) AU739544B2 (da)
CA (1) CA2240571C (da)
CH (1) CH693255A5 (da)
DE (1) DE59813465D1 (da)
DK (2) DK1685840T3 (da)
ES (2) ES2262202T3 (da)
PT (2) PT1685840E (da)
RU (1) RU2226099C2 (da)
TW (1) TW474812B (da)
ZA (1) ZA985129B (da)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997027764A1 (en) * 1996-01-31 1997-08-07 South Alabama Medical Science Foundation Food and vitamin preparations containing the natural isomer of reduced folates
EP1102578A4 (en) * 1998-08-03 2005-05-18 Epigenesis Pharmaceuticals Inc NEW ANALGICAL, ANTIINFLAMMATORY AND WOUND HEALING ACTIVE SUBSTANCE
US20020094970A1 (en) * 2000-12-14 2002-07-18 Ronenn Roubenoff Compositions and methods for treating an arthritic condition
DE10062401A1 (de) * 2000-12-14 2002-06-20 Beiersdorf Ag Verwendung von Folsäure und/oder deren Derivaten zur Herstellung kosmetischer oder dermatologischer Zubereitungen zur Prophylaxe von Schäden an der hauteigenen DNA und/oder zur Reparatur bereits eingetretener Schäden an der hauteigenen DNA
FR2828076B1 (fr) * 2001-07-31 2003-11-07 Olivier Laroche Banquette pour musicien
US8173618B2 (en) * 2003-07-25 2012-05-08 University Of Massachusetts Formulations for reducing neuronal degeneration
SE0303526D0 (sv) * 2003-12-22 2003-12-22 Biofol Ab Chemotherapeutic agents
PL1708690T3 (pl) 2003-11-17 2017-01-31 Biomarin Pharmaceutical Inc. Leczenie fenyloketonurii za pomocą BH4
KR20070084270A (ko) 2004-11-17 2007-08-24 바이오마린 파머수티컬 인크. 안정한 정제 제형물
JP2008523090A (ja) * 2004-12-08 2008-07-03 バイオマリン ファーマシューティカル インコーポレイテッド 新生児肺高血圧症の治療のための方法および組成物
WO2006074416A1 (en) * 2005-01-07 2006-07-13 Health Research Inc. 5-amino-4-imidazolecarboxamide riboside and its nucleobase as potentiators of antifolate transport and metabolism
WO2006119589A2 (en) * 2005-05-11 2006-11-16 Ramaekers, Vincent Prevention and therapy of cerebral folate deficiency
US20060293295A1 (en) * 2005-05-13 2006-12-28 Kai Strothmann Pharmaceutical composition comprising progestogens and/or estrogens and 5-methyl- (6S)-tetrahydrofolate
UY29527A1 (es) 2005-05-13 2006-12-29 Schering Ag Composicinn farmaccutica que contienen gestrgenos y/o estrngenos y 5-metil - (6s) - tetrhidrofolato.
DE102005023301B4 (de) * 2005-05-13 2012-05-31 Bayer Schering Pharma Aktiengesellschaft Pharmazeutische Zusammensetzung enthaltend Gestagene und/oder Estrogene und 5-Methyl-(6S)-tetrahydrofolat
AU2012227235B2 (en) * 2005-05-13 2015-06-11 Bayer Intellectual Property Gmbh Pharmaceutical composition comprising progestogens and/or estrogens and 5-methyl-(6S)-tetrahydrofolate
RU2312674C2 (ru) * 2005-12-28 2007-12-20 Юрий Антонович Кошелев Биологически активная добавка "витабс кардио" для профилактики сердечно-сосудистых заболеваний
US8617597B2 (en) 2006-07-06 2013-12-31 Bayer Intellectual Property Gmbh Pharmaceutical composition containing a tetrahydrofolic acid
KR20090029824A (ko) * 2006-07-06 2009-03-23 바이엘 쉐링 파마 악티엔게젤샤프트 피임용 및 선천성 기형 위험 예방용 제약 제제
CN101489563A (zh) 2006-07-06 2009-07-22 拜耳先灵医药股份有限公司 用于避孕和预防先天性畸形风险的药物制剂
US20080064702A1 (en) * 2006-09-08 2008-03-13 Charalambos Antoniades Use of folates for the prevention and treatment of vascular diseases
LT2545939T (lt) 2007-04-11 2021-03-10 Biomarin Pharmaceutical Inc. Tetrahidrobiopterinas, skirtas gydyti ligas, susijusias supadidėjusiu fenilalanino kiekiu
EP2027855A1 (de) * 2007-08-24 2009-02-25 Bayer Schering Pharma AG Verwendung von Gestagenen in Kombination mit (6S)5-Methyltetrahydrofolat zur Therapie der Endometriose mit gleichzeitiger Verminderung von Therapie-Nebenwirkungen sowie der Verminderung des Risikos angeborener Fehlbildungen bei Eintritt einer Gravidität
US20090060997A1 (en) * 2007-08-27 2009-03-05 Christian Seitz Process for producing a pharmaceutical preparation for therapeutic treatment of endometriosis containing a combination of a gestagen and (6s)-5-methyltetrahydrofolate
US8597640B2 (en) * 2007-10-31 2013-12-03 University Of Massachusetts Lowell Over-the-counter vitamin/nutriceutical formulation that provides neuroprotection and maintains or improves cognitive performance in alzheimer's disease and normal aging
BRPI0908477A2 (pt) * 2008-02-13 2018-03-27 Bayer Schering Pharma Ag sistema de distribuição de medicamento contendo estradiol
EP2303019A4 (en) * 2008-06-25 2013-07-17 Bermans S Iskandar (6S) -5-METHYLTETRAHYDROFOLIC ACID FOR THE TREATMENT OF TISSUE INJURIES
SG177613A1 (en) 2009-07-10 2012-03-29 Linzy O Scott Iii Methods and compositions for treating thyroid-related medical conditions with reduced folates
UY32836A (es) 2009-08-12 2011-03-31 Bayer Schering Pharma Ag Partículas estabilizadas que comprenden 5-metil-(6s)-tetrahidrofolato
EP2575825A4 (en) * 2010-02-12 2014-01-01 Alexander Vuckovic M D Llc COMPOSITIONS AND METHODS FOR TREATING DEPRESSION
US9216178B2 (en) 2011-11-02 2015-12-22 Biomarin Pharmaceutical Inc. Dry blend formulation of tetrahydrobiopterin
US20160053281A1 (en) 2013-08-15 2016-02-25 The University Court Of The University Of Edinburgh Enhanced Expression Of RNA Vectors
WO2016185413A1 (en) 2015-05-20 2016-11-24 Nestec S.A. Modified release formulations
WO2018144088A1 (en) 2016-11-03 2018-08-09 Alexander Vuckovic, M.D., Llc Compositions and methods for treating depression
CA3058252A1 (en) * 2017-03-31 2018-10-04 Merck Patent Gmbh Crystalline sodium salt of 5-methyl-(6s)-tetrahydrofolic acid
EP3609894B1 (en) * 2017-03-31 2024-07-17 Merck Patent GmbH Crystalline sodium salt of 5-methyl-(6s)-tetrahydrofolic acid

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1350160A (en) * 1971-06-29 1974-04-18 Foremost Mckesson Pharmaceutical compositions
IT1229203B (it) * 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
DK0432441T3 (da) * 1989-12-11 1996-07-29 American Cyanamid Co Fremgangsmåde til fremstilling af optisk rene diastereoisomere af tetrahydrofolatforbindelser
CA2082811C (en) * 1990-05-11 2004-11-16 Colin P. Spears 5,10-methylene-tetrahydrofolate as a modulator of a chemotherapeutic agent
CH682664A5 (en) * 1991-10-15 1993-10-29 Eprova Ag Stable salts of 5,10-methylene tetrahydrofolate.
CH684644A5 (de) * 1992-07-13 1994-11-15 Eprova Ag 5,10-Methylentetrahydrofolsäure-Cyclodextrin-Einschlussverbindungen.
ZA936723B (en) * 1992-09-14 1995-08-14 Vesta Med Pty Ltd Pharmaceutical preparations for lowering homocysteine levels
CH689831A5 (de) * 1995-11-07 1999-12-15 Eprova Ag Stabile kristalline Tetrahydrofolsaeure-Salze.
WO1997027764A1 (en) * 1996-01-31 1997-08-07 South Alabama Medical Science Foundation Food and vitamin preparations containing the natural isomer of reduced folates
US6008221A (en) * 1996-11-06 1999-12-28 Bristol-Myers Squibb Company Method for treating Alzheimer's disease with folic acid

Also Published As

Publication number Publication date
US6011040A (en) 2000-01-04
AU7007998A (en) 1998-12-17
JPH11116482A (ja) 1999-04-27
TW474812B (en) 2002-02-01
EP0898965B1 (de) 2006-03-29
DK1685840T3 (da) 2012-04-10
DK0898965T3 (da) 2006-07-31
EP1685840A2 (de) 2006-08-02
RU2226099C2 (ru) 2004-03-27
EP1685840B1 (de) 2011-12-28
CN102151271A (zh) 2011-08-17
EP0898965A2 (de) 1999-03-03
ES2376472T3 (es) 2012-03-14
PT1685840E (pt) 2012-02-09
DE59813465D1 (de) 2006-05-18
EP0898965B9 (de) 2006-08-09
AU739544B2 (en) 2001-10-18
ATE321555T1 (de) 2006-04-15
EP1685840A3 (de) 2010-06-02
ES2262202T3 (es) 2006-11-16
EP0898965A3 (de) 2000-11-15
CA2240571A1 (en) 1998-12-13
PT898965E (pt) 2006-08-31
ATE538793T1 (de) 2012-01-15
CH693255A5 (de) 2003-05-15
CA2240571C (en) 2006-08-08

Similar Documents

Publication Publication Date Title
ZA985129B (en) The use of tetrahydrofolates in natural stereoisomeric form for the production of a pharmaceutical preparation suitable for influencing the homocysteine level particularly for asissting the remethylation of homocysteine
WO1999045949A3 (en) Use of follistatin to modulate gdf-8 and bmp-11
WO2002058684A3 (en) Combinations of drugs (e.g., chlorpromazine and pentamidine) for the treatment of neoplastic disorders
HU9600657D0 (en) K-252a derivatives which enhance neurotrophin-induced activity
Siniscalchi et al. Increase in plasma homocysteine levels induced by drug treatments in neurologic patients
AU4830097A (en) Use of an extract of Cimicifuga
IL148963A0 (en) Composition for the prevention and/or treatment of circulatory disorders, comprising derivatives of l-carnitine and extracts of ginkgo biloba
HK1049105A1 (zh) 磷酸二酯酶4抑制剂的使用方法
Rubin Art therapy: What it is and what it is not.
WO2004108069A3 (en) Compositions and methods for promoting neuronal outgrowth
EP1105145A4 (en) METHOD AND PHARMACEUTICAL COMPOSITION FOR REDUCING THE PLASMATIC CONCENTRATION OF HOMOCYSTEIN
NO984572D0 (no) Anvendelse av 2,5-dihydroksybenzensulfonderivater for fremstilling av legemidler ment for normalisering av den endoteliale funksjon, for behandling av seksuell dysfunksjon og vaskulµre komplikasjoner i diabetes, sÕvel som vaskulµre lidelser av e
Kral et al. Relationship of vitamin B12 and folic acid to memory function.
ATE286402T1 (de) Verwendung von morinda citrifolia zur behandlung von tinnitus
IL120521A0 (en) Use of bradykinin antagonists for the production of pharmaceuticals for the treatment of chronic fibrogenetic liver disorders and acute liver disorders
WO2001064203A3 (en) Composition for the prevention and/or treatment of vascular diseases, comprising propionyl l-carnitine and coenzyme q¿10?
Dilsaver Onset of winter depression earlier than generally thought?
EP0745597A3 (en) Novel melatonergic indanyl piperazines or homopiperazines
AU6458290A (en) 3-substituted-2-oxindole derivatives as inhibitors of interleukin-1 biosynthesis
Schaffer et al. Barrett's syndrome presenting as globus hystericus.
AU2427300A (en) Use of extracts from ginkgo biloba leaves for treating sleep disorders
WO2001043757A3 (en) Composition comprising ingredients of panax ginseng and ginko biloba
Order et al. Memory Stacks: Combining Supplements for Best Results
Order et al. The Role of B Vitamins in Boosting Brain Power and Mental Focus
Order et al. Probiotics and the Gut-Brain Connection in OCD